Literature DB >> 1651159

The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice.

T Yoneda1, R M Lyall, M M Alsina, P E Persons, A P Spada, A Levitzki, A Zilberstein, G R Mundy.   

Abstract

Many human tumors of epithelial origin contain cells overexpressing the epidermal growth factor (EGF) receptor, and there is convincing evidence that cancer cell growth is correlated with the loss of the normal regulation of the EGF receptor signal transduction pathway. Some cancers are clearly dependent on activation of the EGF receptor for their proliferation. Recently, a class of compounds, tyrphostins, which inhibit the protein tyrosine kinase activity of the growth factor receptor, have been described. In this report, we have examined the antiproliferative effects of potent new tyrphostins on a well-characterized human squamous cell carcinoma in vitro and in vivo. We found that two of these compounds (RG-13022 and RG-14620) suppressed not only EGF-stimulated cancer cell proliferation in vitro but also tumor growth in nude mice. RG-13022 also increased the life span of these tumor-bearing nude mice. When administered to tumor-bearing nude mice together with monoclonal antibodies to the EGF receptor at a suboptimal dose which had no effect alone, inhibition of tumor growth was markedly enhanced. These data suggest that tyrphostins have potential as anticancer agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651159

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line.

Authors:  Yong He; Jun Zhou; Jin-Sheng Wu; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 2.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.064

3.  Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.

Authors:  R Asslan; A Pradines; G Favre; F Le Gaillard
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 4.  Cell-signaling targets for antitumour drug development.

Authors:  V G Brunton; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.

Authors:  B Kullenberg; C Jansen; N Fredäng; B Ohlsson; J Axelson
Journal:  Int J Pancreatol       Date:  2000-12

6.  Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.

Authors:  J C López-Talavera; A Levitzki; M Martínez; A Gazit; R Esteban; J Guardia
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

7.  von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays.

Authors:  Stefanie Galbán; Jinshui Fan; Jennifer L Martindale; Chris Cheadle; Bryan Hoffman; Michael P Woods; Gretchen Temeles; Jürgen Brieger; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice.

Authors:  M W Kunkel; K E Hook; C T Howard; S Przybranowski; B J Roberts; W L Elliott; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 9.  Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.

Authors:  A E Wakeling; A J Barker; D H Davies; D S Brown; L R Green; S A Cartlidge; J R Woodburn
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

10.  Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Sung-Han Hsiao; Megumi Murakami; Ming-Jie Lu; Yan-Qing Li; Chia-Hung Hsieh; Suresh V Ambudkar; Yu-Shan Wu
Journal:  Cancer Lett       Date:  2017-09-08       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.